- Active not recruitingPHASE2
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
This study is testing a new drug, BNT327, for advanced breast cancer (called triple-negative). Researchers want to see if it's safe and works well when given with chemotherapy. It's for people whose cancer has spread or is difficult to treat.
For: Locally Advanced Breast Cancer · Triple Negative Breast Cancer · Metastatic Triple Negative Breast CancersUnited States · Australia · Turkey (Türkiye) - RecruitingPHASE3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This study is looking into a new drug called Pumitamig for people with a type of breast cancer called triple-negative breast cancer. It compares Pumitamig plus standard chemotherapy with a dummy drug (placebo) plus chemotherapy to see if it's safe and effective.
For: Breast NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE2
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
This study is for people with HER2-positive breast cancer that has spread. It's testing a new drug called evorpacept alongside standard treatments like trastuzumab and chemotherapy. Researchers want to see if this combination is safe and helps people whose cancer has grown despite previous treatments.
For: Breast Cancer, MetastaticUnited States · Canada · France - RecruitingPHASE3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
This study looks at two drug combinations for HER2-positive breast cancer that has spread. It compares a new drug, zanidatamab, with a standard drug, trastuzumab, both given with chemotherapy, to see which works best and is safest after previous treatments haven't worked.
For: Metastatic HER2-positive Breast CancerUnited States · Australia · Austria - Active not recruitingPHASE3
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
This study tests a new drug, Dato-DXd, for advanced breast cancer. It compares Dato-DXd to standard chemotherapy in women whose cancer is HR-positive and HER2-negative and has already been treated with other chemotherapy. Researchers want to see if Dato-DXd works better.
For: Breast CancerUnited States · Argentina · Belgium - Active not recruitingPHASE3
Detect V / CHEVENDO (Chemo vs. Endo)
This study compares different treatments for advanced breast cancer that has spread. It aims to see if a combination of targeted therapies and hormone therapy works better than targeted therapies and chemotherapy, while also keeping quality of life high.
For: Metastatic Breast CancerGermany - Active not recruitingPHASE2
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
This study looks at using detailed tumour gene testing to guide treatment for advanced breast cancer. It compares giving targeted drugs based on these tests with standard chemotherapy or immunotherapy for patients whose cancer has responded well to initial treatment.
For: Metastatic Breast CancerFrance - Active not recruitingPHASE3
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
This study compares a new treatment, INT230-6, to standard care for advanced soft tissue sarcoma, a type of cancer. It's for adults whose cancer has grown despite previous treatments. The main goal is to see if INT230-6 helps people live longer.
For: Sarcoma,Soft TissueUnited States · Canada · France - Active not recruitingPHASE1
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
This study is testing a new drug, ELVN-002, with existing treatments like trastuzumab and chemotherapy. It's for adults with certain advanced HER2-positive cancers, including breast, stomach, and bowel cancer. The main goal is to find a safe dose and see how well it works.
For: HER2-positive Breast Cancer · HER2-positive Gastric Cancer · HER2 Positive Solid TumorsUnited States · Belgium · France - Active not recruitingPHASE3
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study compares a new breast cancer drug, trastuzumab deruxtecan, with standard treatments. It's for people with HER2-low breast cancer that has spread or can't be removed by surgery and who have already had other treatments.
For: Breast CancerUnited States · Austria · Belgium